Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics sold 417 shares of the company's common stock on February 17, 2026, at a sale price of $27.59 per share, yielding proceeds of $11,505.
The trade was disclosed in a Form 4 filed with the Securities and Exchange Commission and was carried out pursuant to a Rule 10b5-1 trading plan that Rodman adopted on October 6, 2025. The filing also reports that Rodman exercised options to acquire 417 shares at an exercise price of $15.44 per share, an exercise transaction valued at $6,438.
After completing the sale and option exercise, Rodman directly owns 44,089 shares of Mineralys Therapeutics. The company's stock has appreciated substantially in the past year, rising 191% according to InvestingPro data, with the share price reported at $27.94 at the time of the latest market quote.
Mineralys, which has a market capitalization of $2.18 billion, is currently rated a Strong Buy by analysts, with published price targets that span from $42 to $56. Investors are also approaching an upcoming corporate milestone: the company is scheduled to report earnings on March 18.
Recent analyst activity includes Stifel raising its stock price target to $52 while maintaining a Buy rating. That update followed the release of strong clinical trial data for lorundrostat, Mineralys' lead investigational therapy targeting uncontrolled or resistant hypertension. The company is preparing a New Drug Application for lorundrostat, reflecting advancement in its development timeline.
Additionally, the Phase 3 Launch-HTN clinical trial for lorundrostat received recognition in JAMA's inaugural Research of the Year Roundup. The study was named among nine papers identified as the most impactful studies published between October 2024 and September 2025, with JAMA editors featuring the trial under the title "New Hope for Treatment-Resistant Hypertension." These acknowledgments underscore the trial's prominence within the medical literature.
Investors and market observers will likely monitor the scheduled earnings release, ongoing analyst coverage, and regulatory progress for lorundrostat as the company moves forward. The filings documenting Rodman's sale and option exercise provide a contemporaneous snapshot of insider activity alongside broader clinical and market developments for Mineralys Therapeutics.
Summary of the transactions and corporate context
- Rodman sold 417 shares at $27.59 on February 17, 2026, for $11,505.
- He exercised options to buy 417 shares at $15.44 for a total exercise amount of $6,438.
- Post-transactions, Rodman directly holds 44,089 shares.
- Mineralys is preparing an NDA for lorundrostat and has a Phase 3 trial recognized by JAMA.